Genelux (GNLX) Cash from Operations (2022 - 2026)
Genelux's (GNLX) quarterly Cash from Operations came in at 6059000.0 in Q1 2026, down 11.48% year-on-year from 6844869.05 in Q1 2025, and up 2.26% quarter-over-quarter from 6199000.0 in Q4 2025.
Genelux (GNLX) Cash from Operations (2022 - 2026) Analysis & Trends
Genelux's Cash from Operations history runs 5 years deep, the most recent figure standing at 6059000.0 for Q1 2026.
- On a quarterly basis, Cash from Operations fell 11.48% year-over-year to 6059000.0 in Q1 2026; TTM through Mar 2026 was 25892000.0, a 16.06% decrease from a year earlier, with the FY2025 full-year figure at 25268000.0, down 19.03% from the prior year.
- Cash from Operations advanced to 6059000.0 in Q1 2026 per GNLX's latest filing, from 6199000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 2825000.0 in Q1 2022 and bottomed at 7065000.0 in Q2 2025.
- The 5-year median for Cash from Operations is 5435000.0 (2025), against an average of 4768200.0.
- Across the five-year window, Cash from Operations slumped 355.2% in 2023 and jumped 37.74% in 2024, its largest moves.
- Year by year, Cash from Operations stood at 1518000.0 in 2022, then plunged by 355.2% to 6910000.0 in 2023, then soared by 37.74% to 4302000.0 in 2024, then slumped by 44.1% to 6199000.0 in 2025, then climbed by 2.26% to 6059000.0 in 2026.
- Per Business Quant, the three latest GNLX Cash from Operations figures stand at 6059000.0 (Q1 2026), 6199000.0 (Q4 2025), and 6569000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Genelux | 128.48 Mn | 128.48 Mn | - | -6.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.06 Mn |
| Mar 31, 2026 | -6.06 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Sep 30, 2025 | -6.57 Mn |
| Sep 30, 2025 | -6.57 Mn |
| Jun 30, 2025 | -7.07 Mn |
| Jun 30, 2025 | -7.07 Mn |
| Mar 31, 2025 | -5.44 Mn |
| Mar 31, 2025 | -5.44 Mn |
| Dec 31, 2024 | -4.30 Mn |
| Dec 31, 2024 | -4.30 Mn |
| Sep 30, 2024 | -5.75 Mn |
| Sep 30, 2024 | -5.75 Mn |
| Jun 30, 2024 | -6.82 Mn |
| Jun 30, 2024 | -6.82 Mn |
| Mar 31, 2024 | -4.35 Mn |
| Mar 31, 2024 | -4.35 Mn |
| Dec 31, 2023 | -6.91 Mn |
| Dec 31, 2023 | -6.91 Mn |